This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shaneyfelt, T. Articles by Mantzoros, C. S. Search for Related Content PubMed PubMed Citation Articles by Shaneyfelt, T. Articles by Mantzoros, C. S. Social Bookmarking                            What's this?

Hormonal Predictors of Prostate Cancer: A Meta-Analysis

From the Divisions of Endocrinology and Oncology, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, and Harvard School of Public Health, Boston, MA.

Address reprint requests to Christos S. Mantzoros, MD, Division of Endocrinology, RN 325, Beth Israel Deaconess Medical Center, Harvard Medical School, 99 Brookline Ave, Boston, MA 02215; email cmantzor{at}bidmc.harvard.edu

PURPOSE: Although there is strong circumstantial evidence that androgens are implicated in the etiology of prostate cancer, epidemiologic investigations have failed to demonstrate consistently that one or more steroid hormones are implicated. In contrast, recent epidemiologic studies unequivocally link serum insulin-like growth factor 1 (IGF-1) levels with risk for prostate cancer.

METHODS: We have performed the first meta-analysis of all previously published studies on hormonal predictors of risk for prostate cancer.

RESULTS: A meta-analysis restricted to studies that performed mutual adjustment for all measured serum hormones, age, and body mass index indicated that men whose total testosterone is in the highest quartile are 2.34 times more likely to develop prostate cancer (95% confidence interval, 1.30 to 4.20). In contrast, levels of dihydrotestosterone and estradiol do not seem to play a role of equal importance. The only study that provides multivariably adjusted sex hormone–binding globulin data indicates that this binding protein is inversely related to prostate cancer risk (odds ratio, 0.46; 95% confidence interval, 0.24 to 0.89). Finally, all three studies that examined the role of serum IGF-1 have consistently demonstrated a positive and significant association with prostate cancer risk that is similar in magnitude to that of testosterone.

CONCLUSION: Men with either serum testosterone or IGF-1 levels in upper quartile of the population distribution have an approximately two-fold higher risk for developing prostate cancer.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Svensson and B.-A. Bengtsson Safety aspects of GH replacement Eur. J. Endocrinol., November 1, 2009; 161(S1): S65 - S74. [Abstract] [Full Text] [PDF]

				T. Pischon, H. Boeing, S. Weikert, N. Allen, T. Key, N. F. Johnsen, A. Tjonneland, M. T. Severinsen, K. Overvad, S. Rohrmann, et al. Body Size and Risk of Prostate Cancer in the European Prospective Investigation into Cancer and Nutrition Cancer Epidemiol. Biomarkers Prev., November 1, 2008; 17(11): 3252 - 3261. [Abstract] [Full Text] [PDF]

				M. Fukui, M. Tanaka, M. Kadono, S. Imai, G. Hasegawa, T. Yoshikawa, and N. Nakamura Serum Prostate-Specific Antigen Levels in Men With Type 2 Diabetes Diabetes Care, May 1, 2008; 31(5): 930 - 931. [Abstract] [Full Text] [PDF]

				J. A. Darbinian, A. M. Ferrara, S. K. Van Den Eeden, C. P. Quesenberry Jr., B. Fireman, and L. A. Habel Glycemic Status and Risk of Prostate Cancer Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 628 - 635. [Abstract] [Full Text] [PDF]

				E. Hormones and Prostate Cancer Collaborative Group Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies J Natl Cancer Inst, February 6, 2008; 100(3): 170 - 183. [Abstract] [Full Text] [PDF]

				J. Kaeding, J. Belanger, P. Caron, M. Verreault, A. Belanger, and O. Barbier Calcitrol (1{alpha},25-dihydroxyvitamin D3) inhibits androgen glucuronidation in prostate cancer cells Mol. Cancer Ther., February 1, 2008; 7(2): 380 - 390. [Abstract] [Full Text] [PDF]

				E. B. Askew, R. T. Gampe Jr., T. B. Stanley, J. L. Faggart, and E. M. Wilson Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone J. Biol. Chem., August 31, 2007; 282(35): 25801 - 25816. [Abstract] [Full Text] [PDF]

				J. M. Hamilton-Reeves, S. A. Rebello, W. Thomas, J. W. Slaton, and M. S. Kurzer Isoflavone-Rich Soy Protein Isolate Suppresses Androgen Receptor Expression without Altering Estrogen Receptor-{beta} Expression or Serum Hormonal Profiles in Men at High Risk of Prostate Cancer J. Nutr., July 1, 2007; 137(7): 1769 - 1775. [Abstract] [Full Text] [PDF]

				J. P. Mills, P. W. Simon, and S. A. Tanumihardjo {beta}-Carotene from Red Carrot Maintains Vitamin A Status, but Lycopene Bioavailability Is Lower Relative to Tomato Paste in Mongolian Gerbils J. Nutr., June 1, 2007; 137(6): 1395 - 1400. [Abstract] [Full Text] [PDF]

				S. J. Freedland and E. A. Platz Obesity and Prostate Cancer: Making Sense out of Apparently Conflicting Data Epidemiol. Rev., May 3, 2007; (2007) mxm006v1. [Abstract] [Full Text] [PDF]

				K. Michalakis, C. J. Williams, N. Mitsiades, J. Blakeman, S. Balafouta-Tselenis, A. Giannopoulos, and C. S. Mantzoros Serum Adiponectin Concentrations and Tissue Expression of Adiponectin Receptors Are Reduced in Patients with Prostate Cancer: A Case Control Study Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 308 - 313. [Abstract] [Full Text] [PDF]

				J. S. Kasper and E. Giovannucci A Meta-analysis of Diabetes Mellitus and the Risk of Prostate Cancer. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2056 - 2062. [Abstract] [Full Text] [PDF]

				J. K. Campbell, C. K. Stroud, M. T. Nakamura, M. A. Lila, and J. W. Erdman Jr. Serum Testosterone Is Reduced Following Short-Term Phytofluene, Lycopene, or Tomato Powder Consumption in F344 Rats J. Nutr., November 1, 2006; 136(11): 2813 - 2819. [Abstract] [Full Text] [PDF]

				E. S. Ford and S. Liu Invited Commentary: Acne in Adolescence--Protecting the Heart but Damaging the Prostate Later in Life? Am. J. Epidemiol., June 15, 2005; 161(12): 1102 - 1106. [Full Text] [PDF]

				C. Wang, D. H. Catlin, B. Starcevic, D. Heber, C. Ambler, N. Berman, G. Lucas, A. Leung, K. Schramm, P. W. N. Lee, et al. Low-Fat High-Fiber Diet Decreased Serum and Urine Androgens in Men J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3550 - 3559. [Abstract] [Full Text] [PDF]

				B. L. Dillingham, B. L. McVeigh, J. W. Lampe, and A. M. Duncan Soy Protein Isolates of Varying Isoflavone Content Exert Minor Effects on Serum Reproductive Hormones in Healthy Young Men J. Nutr., March 1, 2005; 135(3): 584 - 591. [Abstract] [Full Text] [PDF]

				H. L. Parnes, I. M. Thompson, and L. G. Ford Prevention of Hormone-Related Cancers: Prostate Cancer J. Clin. Oncol., January 10, 2005; 23(2): 368 - 377. [Abstract] [Full Text] [PDF]

				J. A. Laukkanen, D. E. Laaksonen, L. Niskanen, E. Pukkala, A. Hakkarainen, and J. T. Salonen Metabolic Syndrome and the Risk of Prostate Cancer in Finnish Men: A Population-Based Study Cancer Epidemiol. Biomarkers Prev., October 1, 2004; 13(10): 1646 - 1650. [Abstract] [Full Text] [PDF]

				M. J. Steggall and A. Lee Screening and treatment for prostate cancer: The evidence and implications for practice Journal of Research in Nursing, September 1, 2004; 9(5): 322 - 333. [Abstract] [PDF]

				E. Nieschlag, H.M. Behre, P. Bouchard, J.J. Corrales, T.H. Jones, G.K. Stalla, S.M. Webb, and F.C.W. Wu Testosterone replacement therapy: current trends and future directions Hum. Reprod. Update, September 1, 2004; 10(5): 409 - 419. [Abstract] [Full Text] [PDF]

				J. Svensson, B.-A. Bengtsson, T. Rosen, A. Oden, and G. Johannsson Malignant Disease and Cardiovascular Morbidity in Hypopituitary Adults with or without Growth Hormone Replacement Therapy J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3306 - 3312. [Abstract] [Full Text] [PDF]

				K. Zhu, I-M. Lee, H. D. Sesso, J. E. Buring, R. S. Levine, and J. M. Gaziano History of Diabetes Mellitus and Risk of Prostate Cancer in Physicians Am. J. Epidemiol., May 15, 2004; 159(10): 978 - 982. [Abstract] [Full Text] [PDF]

				M. F. Leitzmann, E. A. Platz, M. J. Stampfer, W. C. Willett, and E. Giovannucci Ejaculation Frequency and Subsequent Risk of Prostate Cancer JAMA, April 7, 2004; 291(13): 1578 - 1586. [Abstract] [Full Text] [PDF]

				C.J. Malkin, P.J. Pugh, T.H. Jones, and K.S. Channer Testosterone for secondary prevention in men with ischaemic heart disease? QJM, July 1, 2003; 96(7): 521 - 529. [Full Text] [PDF]

				S. Bhasin, A. B. Singh, R. P. Mac, B. Carter, M. I. Lee, and G. R. Cunningham Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan J Androl, May 1, 2003; 24(3): 299 - 311. [Full Text] [PDF]

				D. J. Hryb, A. M. Nakhla, S. M. Kahn, J. St. George, N. C. Levy, N. A. Romas, and W. Rosner Sex Hormone-binding Globulin in the Human Prostate Is Locally Synthesized and May Act as an Autocrine/Paracrine Effector J. Biol. Chem., July 12, 2002; 277(29): 26618 - 26622. [Abstract] [Full Text] [PDF]

				M. Stanbrough, I. Leav, P. W. L. Kwan, G. J. Bubley, and S. P. Balk Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium PNAS, September 4, 2001; (2001) 191235898. [Abstract] [Full Text] [PDF]

				T. Nickerson, F. Chang, D. Lorimer, S. P. Smeekens, C. L. Sawyers, and M. Pollak In Vivo Progression of LAPC-9 and LNCaP Prostate Cancer Models to Androgen Independence Is Associated with Increased Expression of Insulin-like Growth Factor I (IGF-I) and IGF-I Receptor (IGF-IR) Cancer Res., August 1, 2001; 61(16): 6276 - 6280. [Abstract] [Full Text] [PDF]

				T. W.-M. Boileau, S. K. Clinton, S. Zaripheh, M. H. Monaco, S. M. Donovan, and J. W. Erdman Jr. Testosterone and Food Restriction Modulate Hepatic Lycopene Isomer Concentrations in Male F344 Rats J. Nutr., June 1, 2001; 131(6): 1746 - 1752. [Abstract] [Full Text]

				M. Sumitomo, M. I. Milowsky, R. Shen, D. Navarro, J. Dai, T. Asano, M. Hayakawa, and D. M. Nanus Neutral Endopeptidase Inhibits Neuropeptide-mediated Transactivation of the Insulin-like Growth Factor Receptor-Akt Cell Survival Pathway Cancer Res., April 1, 2001; 61(8): 3294 - 3298. [Abstract] [Full Text]

				E. M. Erfurth, B. Bülow, Z. Mikoczy, and L. Hagmar Incidence of a Second Tumor in Hypopituitary Patients Operated for Pituitary Tumors J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 659 - 662. [Abstract] [Full Text]

				A. C. Paterson, K. S. Leeding, L. A. Bach, G. S. Baldwin, F. A. Macrae, and A. Shulkes More About: Prospective Study of Colorectal Cancer Risk in Men and Plasma Levels of Insulin-Like Growth Factor (IGF)-I and IGF-Binding Protein-3 J Natl Cancer Inst, December 6, 2000; 92(23): 1947a - 1948a. [Full Text] [PDF]

				X. Zi, J. Zhang, R. Agarwal, and M. Pollak Silibinin Up-Regulates Insulin-like Growth Factor-Binding Protein 3 Expression and Inhibits Proliferation of Androgen-independent Prostate Cancer Cells Cancer Res., October 1, 2000; 60(20): 5617 - 5620. [Abstract] [Full Text]

				M. Stanbrough, I. Leav, P. W. L. Kwan, G. J. Bubley, and S. P. Balk Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium PNAS, September 11, 2001; 98(19): 10823 - 10828. [Abstract] [Full Text] [PDF]